Multiple Myeloma Clinical Trials & Research Studies Near You (Updated 6/24)

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06399393

Recruiting

The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).

Gender:

All

Ages:

18 years and above

Trial Updated:

05/01/2024

Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +117 locations

Banner MD Anderson Cancer Center, Gilbert, Arizona

Mayo Clinic in Arizona - Scottsdale, Scottsdale, Arizona

UCLA Hematology/Oncology - Westwood (Building 200 Suite 120), Los Angeles, California

University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange, California

University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento, California

Colorado Blood Cancer Institute, Denver, Colorado

Yale University School of Medicine, New Haven, Connecticut

Mayo Clinic in Florida, Jacksonville, Florida

AdventHealth Orlando, Orlando, Florida

Moffitt Cancer Center, Tampa, Florida

Winship Cancer Institute, Emory University, Atlanta, Georgia

Northside Hospital, Atlanta, Georgia

Massachusetts General Hospital, Boston, Massachusetts

Boston Medical Center, Boston, Massachusetts

Local Institution - 0123, Ann Arbor, Michigan

Ascension Providence Hospital, Southfield, Michigan

Local Institution - 0119, Minneapolis, Minnesota

Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota

Washington University School of Medicine, Saint Louis, Missouri

Columbia University Irving Medical Center, New York, New York

Novant Health Cancer Institute - Elizabeth, Charlotte, North Carolina

Wake Forest Baptist Health, Winston-Salem, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

St. David's South Austin Medical Center, Austin, Texas

UT Southwestern Medical Center, Dallas, Texas

Houston Methodist Hospital, Houston, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

Local Institution - 0136, Richmond, Virginia

Royal Prince Alfred Hospital, Camperdown, New South Wales

Local Institution - 0005, Brisbane, Queensland

Peter MacCallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

St Vincent's Hospital, Melbourne, Victoria

Fiona Stanley Hospital, Murdoch, Western Australia

Uniklinikum Salzburg, Salzburg, Not set

Medizinische Universität Wien, Wien, Not set

Institut Jules Bordet, Anderlecht, Bruxelles-Capitale, Région De

UZ Brussel, Brussels, Bruxelles-Capitale, Région De

Local Institution - 0133, Edmonton, Alberta

Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario

Local Institution - 0134, Montreal, Quebec

Local Institution - 0036, Brno, Brno-město

Local Institution - 0034, Hradec Kralove, Hradec Králové

Local Institution - 0035, Olomouc, Olomoucký Kraj

Local Institution - 0033, Praha 2, Not set

Local Institution - 0070, Odense, Syddanmark

CHU Bordeaux Haut-Leveque, Pessac, Aquitaine

Institut Paoli-Calmettes, Marseille, Bouches-du-Rhône

Hopital Claude Huriez - CHU de Lille, Lille, Nord

Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu, Nantes, Pays-de-la-Loire

Centre Hospitalier Lyon Sud, Pierre-Bénite, Rhône

Henri Mondor Hospital, Créteil, Val-de-Marne

Gustave Roussy, Villejuif, Val-de-Marne

Local Institution - 0029, Poitiers, Vienne

Hôpital Saint-Louis, Paris, Not set

Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE, Toulouse, Not set

Hôpital Saint Antoine, Paris, Île-de-France

Local Institution - 0072, Heidelberg, Baden-Württemberg

Local Institution - 0078, Ulm, Baden-Württemberg

Local Institution - 0077, Nuremberg, Bayern

Local Institution - 0073, Köln, Nordrhein-Westfalen

Local Institution - 0079, Dresden, Sachsen

Local Institution - 0087, Leipzig, Sachsen

Local Institution - 0075, Kiel, Schleswig-Holstein

Local Institution - 0115, Essen, Not set

Local Institution - 0076, Hamburg, Not set

Local Institution - 0074, Wuerzburg, Not set

University Hospital of Patras, Patras, Achaḯa

Evangelismos General Hospital of Athens, Athens, Attikí

Attikon General University Hospital, Chaidari, Attikí

G. Papanikolaou General Hospital, Thessaloniki, Thessaloníki

Local Institution - 0055, Be'er Sheva, HaDarom

Local Institution - 0058, Petah-Tikva, HaMerkaz

Sheba Medical Center, Ramat Gan, HaMerkaz

Sourasky Medical Center, Tel Aviv, Tell Abīb

Rambam Health Care Campus, Haifa, Not set

Hadassah Medical Center, Jerusalem, Not set

Humanitas, Rozzano, Milano

Local Institution - 0067, Torino, Piemonte

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Not set

AOU Policlinico Umberto I, Roma, Not set

Nagoya City University Hospital, Nagoya, Aichi

Hokkaido University Hospital, Sapporo, Hokkaido

Hyogo Medical University Hospital, Nishinomiya, Hyogo

Kanazawa University Hospital, Kanazawa, Ishikawa

Tokai University Hospital, Isehara, Kanagawa

Chiba University Hospital, Chiba, Not set

Local Institution - 0054, Fukuoka, Not set

Okayama University Hospital, Okayama, Not set

Local Institution - 0071, Shimotsuke, Not set

Local Institution - 0050, Tokyo, Not set

Local Institution - 0041, Hwasun Gun, Jeonranamdo

Local Institution - 0039, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0040, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0038, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0043, Seoul, Seoul-teukbyeolsi [Seoul]

Oslo Universitetssykehus Rikshospitalet, Oslo, Not set

Centrum Onkologii Ziemi Lubelskiej, Lublin, Lubelskie

Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Warsaw, Mazowieckie

Instytut Hematologii i Transfuzjologii, Warsaw, Mazowieckie

Uniwersyteckie Centrum Kliniczne, Gdańsk, Not set

Uniwersytecki Szpital Kliniczny w Poznaniu, Poznań, Not set

Narodowy Instytut Onkologii - Oddzial w Gliwicach, Gliwice, Śląskie

Institutul Clinic Fundeni, Bucharest, Not set

Institut Català d'Oncologia (ICO) - Badalona, Badalona, Barcelona [Barcelona]

Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet Del Llobregat, Barcelona [Barcelona]

Hospital Clínic de Barcelona, Barcelona, Catalunya [Cataluña]

Clinica Universidad de Navarra, Pamplona, Navarra

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Not set

Hospital Universitari i Politecnic La Fe, València, Not set

Local Institution - 0093, Birmingham, England

Local Institution - 0080, London, London, City Of

Local Institution - 0094, London, London, City Of

Local Institution - 0081, Glasgow, Not set

Conditions: Multiple Myeloma

Register for Updates

Learn More ›

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

NCT04756726

Recruiting

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered according to different dosing schedules as a single agent and in combination with dexamethasone (in MM subjects only).

Gender:

All

Ages:

18 years and above

Trial Updated:

04/30/2024

Locations: Mayo Clinic, Phoenix, Arizona +12 locations

Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's

Register for Updates

Learn More ›

TriPRIL CAR T Cells in Multiple Myeloma

NCT05020444

Recruiting

This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. TriPRIL CAR T Cells Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

Gender:

All

Ages:

18 years and above

Trial Updated:

04/26/2024

Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma

Register for Updates

Learn More ›

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

NCT05911321

Recruiting

This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to multiple myeloma that has returned or has not responded to prior treatment. The study will specifically investigate the impact of administering lower-than-standard doses of pomalidomide and dexamethasone. Using lower doses of pomalidomide and dexamethasone in this setting h... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/25/2024

Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina +2 locations

Conditions: Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidity

Register for Updates

Learn More ›

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

NCT05561751

Recruiting

This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arms: GPC-100 in combination with propranolol; or GPC-100 in combination with propranolol and G-CSF. To characterize the safety and clinical activity of GPC-100, the study will employ a Bayesian... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/24/2024

Locations: University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California +9 locations

Conditions: Multiple Myeloma

Register for Updates

Learn More ›

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

NCT06048250

Recruiting

This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor [CAR] T-cell therapy) in patients with multiple myeloma that has come back after a period of improvement (relapsed). CC-92480 works by binding to a protein called CRBN that triggers the breakdown of proteins: Ikaros and Aiolos, leading to cell death in multiple myeloma cells. Giving mezigdomide after Abecma CAR T cell... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/24/2024

Locations: City of Hope Medical Center, Duarte, California

Conditions: Multiple Myeloma

Register for Updates

Learn More ›

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

NCT04771572

Recruiting

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

Gender:

All

Ages:

13 years and above

Trial Updated:

04/23/2024

Locations: University of Chicago, Chicago, Illinois +7 locations

Conditions: Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase

Register for Updates

Learn More ›

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

NCT03672318

Recruiting

The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by binding those bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that... Read More

The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by binding those bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. Both antibodies and T cells have been used to treat subjects with cancers. They both have shown promise, but neither alone has been sufficient to cure most subjects. This study is designed to combine both T cells and antibodies to create a more effective treatment. The treatment that is being researched is called autologous T lymphocyte chimeric antigen receptor cells targeted against the CD138 antigen (CAR138 T cells). In previous studies, it has been shown that a new gene can be put into T cells that will increase their ability to recognize and kill cancer cells. A gene is a unit of DNA. Genes make up the chemical structure carrying the subject's genetic information that may determine human characteristics (i.e., eye color, height and sex). The new gene that is put in the T cells in this study makes a piece of an antibody called anti-CD138. This antibody floats around in the blood and can detect and stick to cancer cells called multiple myeloma cells because they have a substance on the outside of the cells called CD138. Anti-CD138 antibodies have been used to treat people with multiple myeloma, but have not been strong enough to cure most subjects. For this study, the anti-CD138 antibody has been changed so that instead of floating free in the blood part of it is now joined to the T cells. Only the part of the antibody that sticks to the multiple myeloma cells is attached to the T cells instead of the entire antibody. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD138 chimeric (combination) receptor-activated T cells seem to kill some of the tumor, but they do not last very long in the body and so their chances of fighting the cancer are unknown. Read Less

Gender:

All

Ages:

18 years and above

Trial Updated:

04/22/2024

Locations: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

Conditions: Multiple Myeloma, Immune System Diseases

Register for Updates

Learn More ›

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644

Recruiting

We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel.

Gender:

All

Ages:

Between 18 years and 100 years

Trial Updated:

04/15/2024

Locations: Sanguine Biosciences, Los Angeles, California

Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis

Register for Updates

Learn More ›

PROFAST Intervention in Precursor Multiple Myeloma

NCT05565638

Recruiting

This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and smoldering waldenstrom macroglobulinemia (SWM). The purpose of this study is to understand if fasting for a prolonged period of time during the nighttime hours is a strategy to prevent overweight and obese individuals from developing blood cancer. Participants will be... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/15/2024

Locations: Dana Farber Cancer Institute, Boston, Massachusetts

Conditions: Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS, Fasting, Multiple Myeloma

Register for Updates

Learn More ›

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

NCT05361694

Recruiting

The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/15/2024

Locations: University of Miami Hospitals, Miami, Florida

Conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

Register for Updates

Learn More ›

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT03314974

Recruiting

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).

Gender:

All

Ages:

60 years and below

Trial Updated:

04/15/2024

Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes

Register for Updates

Learn More ›

Multiple Myeloma Clinical Trials

Match to Clinical Trials